The key to the development of new TB drugs—as well as other medical products for low resource countries—has been the formation of partnerships between public and private sectors. This concept was not widely understood or accepted in 1999 when RTI began working in TB drug development. Since that time, RTI has managed the development of drug candidates, prepared economic reports and analyzed statistical data related to TB drug development, and stimulated the involvement of pharmaceutical companies to aid in the commercialization of new drugs.
US & Canadian Academy of Pathology (USCAP)